Intellia Therapeutics, Inc. (NTLA) vs Xeris Biopharma Holdings, Inc. (XERS)
A side-by-side comparison of Intellia Therapeutics, Inc. and Xeris Biopharma Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NTLA
Intellia Therapeutics, Inc.
$12.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
XERS
Xeris Biopharma Holdings, Inc.
$10.07HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — NTLA vs XERS
growth of $100 · dividends reinvested · last 8yNTLA -58.6% (-10.4%/yr)XERS -49.9% (-8.3%/yr)XERS compounded faster over this window
NTLA XERS
NTLA vs XERS: by the numbers
- •XERS is the larger company ($1.74B vs $1.73B market cap).
- •Both run net losses; XERS's is the smaller (-5.12% vs -672.16% net margin).
- •XERS grew revenue faster over the past five years (58.33% vs 7.31% CAGR).
Metrics side by side
Valuation
| Metric | NTLA | XERS |
|---|---|---|
| P/S ratio | 29.05 | 5.18 |
| P/B ratio | 2.38 | N/A |
| EV / EBITDA | N/A | 38.84 |
| FCF yield | N/A | 3.19% |
Profitability
| Metric | NTLA | XERS |
|---|---|---|
| Gross margin | 76.47% | 83.34% |
| Operating margin | -651.67% | 10.91% |
| Net margin | -672.16% | -5.12% |
| ROE | -54.96% | N/A |
| ROIC | -54.45% | 12.79% |
Growth (annualized)
| Metric | NTLA | XERS |
|---|---|---|
| Revenue CAGR (5Y) | 7.31% | 58.33% |
| Total return CAGR (5Y) | -37.13% | 33.72% |
Frequently asked
- Which has grown faster, NTLA or XERS?
- Over the past five years, XERS grew revenue faster — NTLA at a 7.31% CAGR versus XERS at 58.33%.
- How have NTLA and XERS total returns compared?
- Over the past 5 years, NTLA delivered -37.13% and XERS delivered 33.72% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Intellia Therapeutics ROEXeris Biopharma ROEIntellia Therapeutics operating marginXeris Biopharma operating marginIntellia Therapeutics revenue growthXeris Biopharma revenue growthIntellia Therapeutics free cash flowXeris Biopharma free cash flow
Intellia Therapeutics & Xeris Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.